Dupilumab is a fully human monoclonal antibody that has been shown to reduce and downregulate pro-inflammatory cytokines such as interleukin-4 (IL-4) and interleukin-13 (IL-13), which are considered key drivers of AD pathophysiology. We present a case report of a patient with atopic dermatitis coexisting with several comorbidities who was successfully treated with dupilumab. This evidence concerns the gene IL13 and atopic eczema.